Genotüübi mõju NK rakkude käitumisele rakukultuuris
Genotüübi mõju NK rakkude käitumisele rakukultuuris
Genotüübi mõju NK rakkude käitumisele rakukultuuris
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
SISUKORDSISUKORD ....................................................................................................................................2KASUTATUD LÜHENDID .........................................................................................................4SISSEJUHATUS............................................................................................................................61. KIRJANDUSE ÜLEVAADE....................................................................................................71.1. Inimese <strong>NK</strong> rakud.................................................................................................................71.1.1 <strong>NK</strong> <strong>rakkude</strong> fenotüüp......................................................................................................71.1.2 <strong>NK</strong> <strong>rakkude</strong> areng ...........................................................................................................91.1.3 <strong>NK</strong> <strong>rakkude</strong> funktsioon ...................................................................................................91.2 <strong>NK</strong> <strong>rakkude</strong> retseptorid........................................................................................................111.2.1 <strong>NK</strong> raku inhibiitorretseptorid........................................................................................141.2.2 <strong>NK</strong> raku aktivatsiooni regulatsioon ..............................................................................151.3 <strong>NK</strong> <strong>rakkude</strong> poolt vahendatud märklaud<strong>rakkude</strong> tapmismehhanismid...............................161.3.1 Loomulik tsütotoksilisus ...............................................................................................161.3.2 Surmaretseptori ligandi rada .........................................................................................181.3.3 Tsütokiinide sekretsioon ...............................................................................................191.3.4 Antikehast sõltuv rakuline tsütotoksilisus.....................................................................191.4 <strong>NK</strong> <strong>rakkude</strong> kliiniline kasutamine .......................................................................................201.4.1 <strong>NK</strong> <strong>rakkude</strong> roll vereloome tüvi<strong>rakkude</strong> transplantatsioonis........................................201.4.2 <strong>NK</strong> <strong>rakkude</strong> kasutamine vähivastases immunoteraapias ..............................................211.5 <strong>NK</strong> <strong>rakkude</strong> in vitro ekspansioon perifeersetest vere<strong>rakkude</strong>st...........................................231.6 Häired <strong>NK</strong> <strong>rakkude</strong> tsütotoksilises aktiivsuses....................................................................241.7 <strong>NK</strong> <strong>rakkude</strong> tsütotoksilise aktiivsuse mõõtmine .................................................................252. MATERJAL JA METOODIKA ............................................................................................302.1 <strong>NK</strong> <strong>rakkude</strong> kogumine.........................................................................................................302.1.1 Lümfopreparatsioon ......................................................................................................302.2.2 Krüopreservatsioon .......................................................................................................322.2 Inimese seerum ....................................................................................................................322.3 Kasutatud rakuliinid.............................................................................................................322.4 Doonor<strong>rakkude</strong> kultiveerimine ............................................................................................332.5 Kasvajarakuliinide kultiveerimine.......................................................................................332.6 Doonor<strong>rakkude</strong> immunofenotüpiseerimine .........................................................................332